Observational Evaluation of Atopic Dermatitis in Pediatric Patients
← catalyst calendarNCT03687359 · readout in 3,260 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,860actual
Sites
182
Countries
Argentina, Australia, Brazil +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-08-15 | actual | When the study began enrolling |
| Primary completion | 2035-07-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-07-23 | estimated | The whole study's end, after follow-up |
| First posted | 2018-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Intervention
- Other: Standard of care
Primary outcomes
what the primary-completion date above is the date OFPatient demographics
measured Baseline (Month 0)
Medical history of selected atopic diseases and comorbidities
measured Baseline (Month 0)
Age at onset of atopic dermatitis (AD)
measured Baseline (Month 0)
Personal and family history of AD and selected atopic diseases
measured Baseline (Month 0)
All prior and current systemic AD treatment
measured Baseline (Month 0)
All prior and current topical therapy and phototherapy for AD (including dose, route and frequency of administration for all AD treatment)
measured Baseline (Month 0)
Presence/severity of AD and selected atopic comorbid conditions
measured Baseline to Month 120
Therapy for selected atopic comorbid conditions
measured Baseline to Month 120
Publications
- PMID 42609208 — linked by the registry
- PMID 40971133 — linked by the registry
- PMID 39389429 — linked by the registry
- PMID 32209624 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed